Moderna, Inc. (MRNA) Q4 2021 Earnings Results

Moderna Beats on EPS, Stock Up 15.1%

Moderna's strong EPS performance exceeded expectations, leading to a significant stock increase of 15.1%. The positive reaction reflects investor confidence in the company's ongoing vaccine efforts and future growth potential. However, the lack of revenue data and guidance leaves some uncertainty about the company's financial outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$11.29	N/A	+14.82%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed confidence in their current vaccine pipeline. They noted the importance of adapting to changing market conditions.

Management highlighted strong performance in vaccine distribution.

They emphasized ongoing research and development efforts.

Future growth will depend on continued demand for COVID-19 vaccines.

Moderna Beats on EPS, Stock Up 15.1%

Key numbers

Management commentary

Moderna, Inc.

More earnings this week

Moderna Beats on EPS, Stock Up 15.1%

Key numbers

Management commentary